THE GENERAL HOSPITAL CORPORATION CLINICAL TRIAL AGREEMENT (Investigator- Initiated) This Clinical Trial Agreement ("Agreement") is made as of the 28 day of September, 2009 ("Effective Date") between CytoDyn, Inc., a publicly traded corporation...Clinical Trial Agreement • September 29th, 2009 • Cytodyn Inc • Pharmaceutical preparations • Massachusetts
Template Clinical Trial Agreement 2015 – the NetherlandsClinical Trial Agreement • November 12th, 2020
This template clinical trial agreement is created in joint cooperation between the vereniging Samenwerkende Topklinische opleidingsZiekenhuizen (STZ), Nefarma, Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI/AvL) and ACRON, to facilitate conducting clinical trials in The Netherlands. The clauses on termination and publication meet the Directive on the Assessment of the Clinical Trial Agreement of the CCMO.
CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN SCOTTISH HEALTH BOARDS [Name – Clinical Trial] This agreement dated …………………………………… is between […. insert name….] Health Board, constituted pursuant to the...Clinical Trial Agreement • December 3rd, 2020
WHEREAS the Sponsor is a pharmaceutical company involved in the research, development, manufacture and sale of medicines for use in humans
ContractClinical Trial Agreement • July 7th, 2023
ZMLUVA O KLINICKOM SKÚŠANÍ CLINICAL TRIAL AGREEMENT uzatvorená podľa § 269 ods. 2 a nasl. zákona č. 513/1991 Zb. Obchodný zákonník v platnom znení (ďalej len „obchodný zákonník”) (ďalej len „Zmluva“) concluded pursuant to Section 269 (2) of Act no.513/1991 of Coll., the Commercial Code, as amended (hereinafter referred to as the “Commercial Code”) (hereinafter referred to as the “Agreement”) Medzi Between Karyopharm Therapeutics, Inc.so sídlom: 85 Wells Avenue, Newton, MA 02459 USAIČO.: 4637137DIČ: 26-3931704zapísaná v obchodnom registri vedenom štátom Delaware,konajúca prostredníctvom: Stuarta Poultona, viceprezidenta a riaditeľa pre rozvoj (ďalej len “Zadávateľ”) Karyopharm Therapeutics, Inc.Registered office: 85 Wells Avenue, Newton, MA 02459 USAID No.: 4637137VAT No.: 26-3931704Registered with the Commercial Register kept by the State of Delaware. Represented by: Executive Vice President, Chief Development Officer, Stuart Poulton (hereinafter referred to as the “Sponsor”) Karyophar
ContractClinical Trial Agreement • February 19th, 2018
Clinical Trial Agreement Smlouva o klinickém hodnocení The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení(“Smlouva”) je uzavírána mezi následujícími stranami: • Fakultní nemocnice Brno, having a place of business at Jihlavská 20, 625 00 Brno, Czech Republic, Identification number: 65269705, Tax identification number: CZ65269705, Acting by: MUDr. RomanKraus, MBA - Director “Institution”), and • Fakultní nemocnice Brno, se sídlem Jihlavská 20, 625 00 Brno, Česká republika, IČ: 65269705, DIČ: CZ65269705, jednající: MUDr. Roman Kraus, MBA - ředitel (“Zdravotnické zařízení”), a • , born on, having a address at (the “Investigator”),and • , nar., s adresou (“Zkoušející”), a • Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ247 68 651, represented by Mr. AlasdairMacDonald (“Quintiles”), a
Standard Clinical Trial Agreement This Clinical Trial Agreement (“Agreement”), dated as of [xx/xx-xxxx] (“Effective Date”) is made by and between; Institution: (hereinafter called “Institution”) Represented by (hereinafter called ”Principal...Clinical Trial Agreement • November 18th, 2021
The Institution and Sponsor are hereinafter each individually referred to as a “Party” and collectively referred to as the “Parties”.
ContractClinical Trial Agreement • March 11th, 2022 • England and Wales
Clinical Research Organisation Model Clinical Trial Agreement (CRO-mCTa) for investigational Advanced Therapy Medicinal Products
CLINICAL TRIAL AGREEMENT – NON-COMMERCIAL RETROSPECTIVE STUDY NON ZOL SPONSOREDClinical Trial Agreement • January 21st, 2021
This Agreement may only be used as a model for a non-interventional retrospective study in which the past is studied on the basis of information that is already available at the start of the study.
ContractClinical Trial Agreement • March 28th, 2024
INSTRUCTIONS [NTD: In case of Phase IV clinical trials, update references to “Investigational Product” for references to “Clinical Trial Product” here and below – see the wording highlighted in yellow] [NTD: See comments in green for single-site studies] [NTD: See comments in blue for Clinical trials involving the use of medical devices]
ContractClinical Trial Agreement • February 8th, 2024
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ This Clinical Trial Agreement (the “Agreement”) is Between Tato smlouva o klinickém hodnocení („smlouva“) seuzavírámezi společností Janssen – Cilag International N.V.,with registered offices at: Turnhoutseweg 30, 2340 Beerse, BelgiumRegistration No.: BE0461607459Represented by the Power of Attorney by the companyJanssen-Cilag s.r.o.with registered offices at Walterovo náměstí 329/1, 158 00 Praha 5 – Jinonice, Czech RepublicID No.: 27146928 Tax ID: CZ27146928Registered in the Commercial Register at the Municipal Court in Prague, section C, enclosure 99837Bank details: Citibank Europe plc, Organizational Unit Account number: 2043060205/2600Databox: 8jvdhia(“Janssen ”) Janssen – Cilag International N.V.,se sídlem na adrese: Turnhoutseweg 30, 2340 Beerse, BelgieRegistrační č.: BE0461607459zastoupenou na základě plné moci společnostíJanssen-Cilag s.r.o.se sídlem na adrese Walterovo náměstí 329/1, 158 00Praha 5 – Jinonice, Česká republ
ContractClinical Trial Agreement • November 9th, 2022
SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍCLINICAL TRIAL AGREEMENT Klinické hodnocení: CA209-238 Clinical Trial: CA209-238 „Randomizovaná, dvojitě zaslepená studie fáze 3hodnotící nivolumab oproti ipilimumabu při adjuvantní imunoterapii u pacientů s vysokým rizikem recidivy po kompletní resekci melanomu stádia IIIb/c nebo stádia IV.“ “A Phase 3, Randomized, Double-blind Study ofAdjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma. in Subjects who are at High Risk for Recurrence.” dále jen „smlouva“. hereinafter “Agreement”. Fakultní nemocnice Královské Vinohrady Fakultní nemocnice Královské Vinohrady Zastoupená MUDr. Janem Šturmou, CSc., ředitelem Represented by Jan Šturma, MD, CSc., director Šrobárova 1150/50 Šrobárova 1150/50 100 34 Praha 10-Vinohrady 100 34 Praha 10-Vinohrady Česká republika Czech Republic IČO: 00064173 Identification No.: 00064173 DIČ: CZ00064173 Tax Identification No.: CZ00064173 Číslo jednací: KH 15/2
ContractClinical Trial Agreement • November 22nd, 2018
[ČESKÁ REPUBLIKA] [CZECH REPUBLIC] SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ CLINICAL TRIAL AGREEMENT Tato smlouva (dále jen „smlouva“) se uzavírá mezi Biogen Idec Research Limited, se sídlem na adrese Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY, Spojené království (dále jen„Biogen“); This Clinical Trial Agreement (the Agreement) is made between Biogen Idec Research Limited, located at Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY, United Kingdom (the “Biogen”); Fakultní nemocnicí u sv. Anny v Brně, se sídlem na adrese Pekařská 53, 656 91 Brno, Česká republika, Identifikační číslo: 00159816, Daňové identifikační číslo: CZ00159816, zastoupená MUDr. Martinem Pavlíkem, Ph.D., DESA, EDIC, ředitelem (dále jen„Zdravotnické zařízení“); a Fakultní nemocnice u sv. Anny v Brně, located at Pekařská 53, 656 91 Brno, Czech Republic, Identification Number: 00159816, Tax Identification Number: CZ00159816, represented by MUDr. Martin Pavlík, Ph.D., DESA, EDIC, Di
DRAFT AGREEMENT FOR CLINICAL TRIALS Study Protocol n° [INSERT NUMBER] Center: [INSERT NUMBER]Clinical Trial Agreement • August 12th, 2024
BETWEEN VZW VITAZ, RPR 881-291-322, having a place of business at Moerlandstraat 1, 9100 Sint-Niklaas, Belgium, duly represented by Mr. Koen Michiels on behalf of Koen Michiels HCM BV, General Deputy and Prof. Dr. Herman Nys, President hereinafter referred to as the “INSTITUTION”,
CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN GENERAL PRACTICE [Name – Clinical Trial] This agreement dated …………………………………… is between […. insert name of General Practice….] , of [.…insert address….]...Clinical Trial Agreement • October 23rd, 2020
WHEREAS the Sponsor is a pharmaceutical company involved in the research, development, manufacture and sale of medicines for use in humans
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • November 7th, 2023
This agreement (hereinafter referred to as the "Agreement") is concluded on the date of its signing by the last party, as specified on the signature page, between:
ContractClinical Trial Agreement • December 27th, 2019
Clinical Trial Agreement Smlouva o KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení („Smlouva“) je uzavírána mezi následujícími stranami: • Thomayerova nemocnice, located at Vídeňská 800, 140 59 Praha 4 – Krč, Czech Republic, Identification number: 00064190, Tax identification number: CZ00064190, state contributory organization established by the Ministry of Health of the Czech Republic, full text of foundation deed No. MZDR 17268-IV/2012, registered in Companies Registry by Municipal Court in Prague, Section PR, inlet 1043 represented by doc. MUDr. Zdeněk Beneš CSc., Director (the “Institution”); and • Thomayerova nemocnice, se sídlem Vídeňská 800 140 59 Praha 4 – Krč, Česká republika, Identifikační číslo: 000 64 190, Daňové identifikační číslo: CZ00064190, státní příspěvková organizace zřízená Ministerstvem zdravotnictví ČR, úplné znění zřizovací listiny č.j. MZDR 17268-IV/2012, zapsaná v obchodním rejstříku u M
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ This Clinical Trial Agreement (the “Agreement”) is Tato smlouva o klinickém hodnocení („smlouva“)se uzavírá between mezi společností Pharmaceutical Research Associates CZ, s.r.o., Pharmaceutical...Clinical Trial Agreement • June 5th, 2024
(“Institution”) („poskytovatel“) And a xxx xxx Working address xxx adresa pracoviště xxx (“Principal Investigator”) („hlavní zkoušející“) (CRO, Janssen, Institution and Principal Investigator collectively as the "Parties", individually a "Party") (CRO, společnost Janssen, poskytovatel a hlavní zkoušející, dále souhrnně jako „smluvní strany“, jednotlivě jako „smluvní strana“) and effective as of the date of publication into the Register of Contracts in the Czech Republic (“Effective Date”). a účinná k datu uveřejnění v Registru smluv České republiky („datum účinnosti“). Clinical Trial : Phase 2/3, Multistage, Multicenter, Randomized, Double‐Blind, Placebo‐ Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with CIDP Klinické hodnocení : Vícestupňová, multicentrická, randomizovaná, dvojitě zaslepená, placebem kontrolovaná studie fáze 2/3 s paralelní skupinou pro hodnocení účinnosti a bez
ContractClinical Trial Agreement • May 17th, 2021
Clinical Trial Agreement SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána mezi následujícími stranami: Fakultní nemocnice v Motole, having a place of business at V Úvalu 84, Czech Republic, Identification number: 00064203, Tax identification number: CZ00064203,(the “Institution”), and • Fakultní nemocnice v Motole, se sídlem V Úvalu 84, Česká republika, Identifikační číslo: 00064203, Daňové identifikační číslo: CZ00064203,(“Zdravotnické zařízení”), a • Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ247 68 651,(“Quintiles”), and • Quintiles Czech Republic, s.r.o., se sídlem Praha 5, Jinonice, Radlická 714/113a, PSČ 158 00 Praha, Česká republika, IČ: 247 68 651, DIČ: CZ24768651,(“Quintiles”), a • Baxalta Innovations Gmb
SMLOUVAClinical Trial Agreement • August 16th, 2024
(CRO, Center and the Principal Investigator hereinafter collectively referred to as the “Parties” or the “Contracting Parties“)
ContractClinical Trial Agreement • May 11th, 2022
SMLOUVAO KLINICKÉM HODNOCENÍ CLINICAL TRIAL AGREEMENT Mezi Between Sarepta Therapeutics, Inc.,se sídlem 215 First Street, Cambridge, Massachusetts 02142, USA(dále jen „Zadavatel“) Sarepta Therapeutics, Inc.,with its corproporate address at 215 First Street,Cambridge, Massachusetts 02142, USA (hereinafter referred to as the “Sponsor”) A AND Fakultní nemocnice Brnose sídlem: Jihlavská 20, 625 00 Brno, Česká republika, jednající prof. MUDr. Jaroslavem Štěrbou, Ph.D., ředitelem nemocnice IČO: 65269705 DIČ: CZ65269705 (dále jen „Centrum“) Fakultni nemocnice Brno,located at Jihlavska 20, 625 00 Brno, Czech Republic, represeted by prof. MUDr. Jaroslav Štěrba, Ph.D., hospital director Company ID: 65269705 Tax ID: CZ65269705 (hereinafter referred to as the “Center”) A AND xxxtrvalým bydlištěm xxx Datum nar.: xxx(dále jen „Hlavní zkoušející”) xxxpermanent residence xxx DOB: xxx(hereinafter referred to as the “Principal Investigator”) (Centrum a Hlavní zkoušející dále společně označováni jako „Sm
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉ STUDII For Protocol RPC01-3203 pro protokol RPC01-3203 This Clinical Trial Agreement (hereinafter, the “Agreement”) is by and between: Tato smlouva o klinické studii (dále „smlouva”), byla uzavřena mezi...Clinical Trial Agreement • September 21st, 2018
This Agreement is valid as of the last date of signature below (the “Validity Date”). Tato smlouva vstupuje v platnost ke dni posledního podpisu níže (dále „datum platnosti”). WHEREAS VZHLEDEM K TOMU, ŽE (a) The Sponsor conducts business in the development of therapeutic products, compounds, and reagents; (a) Zadavatel podniká ve vývoji léčivých přípravků, látek a činidel; (b) The Institution and the Investigator have acquired expertise in the conduct of clinical trials, and laboratory test evaluations; they have appropriate facilities for the performance of those activities; (b) instituce a zkoušející mají odborné znalosti v provádění klinických hodnocení a hodnocení laboratorních testů a disponují odpovídajícím vybavením pro výkon těchto činností; (c) The Investigator is an employee of the Institution; (c) zkoušející je zaměstnancem instituce; (d) Sponsor requested the Institution and the Investigator to conduct a phase 3 clinical trial “A Phase 3, Multicenter, Randomized, Double-Bli
CLINICAL TRIAL AGREEMENT FOR THE DRUG(S) “__________” BETWEENClinical Trial Agreement • April 15th, 2024
Istituto clinico Humanitas – Humanitas Mirasole S.p.A. shareholder company (hereinafter the “Entity”), headquartered in Rozzano (Milan) Zip code 20089, Via Alessandro Manzoni 56, Tax Code 10125410158, VAT no. 10982360967 , through its Legal Representative Mr. Luciano Ravera , in his capacity as managing director with the powers to enter into this agreement
CONTRACT FOR PERFORMANCE OF CLINICAL TRIAL “ “ EUDRACT No: PROTOCOL CODE: FOUNDATION CODE:Clinical Trial Agreement • June 24th, 2020
Of the one part, Mr/Ms __ and ___ Respectively acting in the name and on behalf of __ (hereinafter, the SPONSOR), with registered office at ____, being empowered for this act by deed of power of attorney No ___, duly registered at the ___ Companies Registry, executed before the Notary of the ___ Notarial Association, Mr/Ms ___, dated ___.
Instruction Pages The information set out below provides a checklist of information that needs to be included in the Primary Care model Clinical Trial Agreement (PC-mCTA) in preparation for execution by the Parties. It is the Sponsor’s responsibility...Clinical Trial Agreement • December 13th, 2023
Add, remove and / or update recitals as applicable to the Clinical Trial (as a preamble to the Agreement, such changes do not constitute modification to the template Agreement). Recital D should be completed where a corporate Affiliate of the Sponsor is formally empowered by the Sponsor to sign the Agreement on behalf of the Sponsor thereby binding the Sponsor as Party to the Agreement (and should be removed where this is not the case). Recital E should be retained if the Trial Site is in Northern Ireland and otherwise deleted.
ZMLUVA 0 KLINICKOM SKÚŠANÍ CLINICAL TRIAL AGREEMENT uzatvorená podľa § 269 ods. 2 a nasl. zákona č. 513/1991 Zb. Obchodný zákonník v platnom znení (ďalej len „Obchodný zákonník”) (ďalej len„Zmluva") concluded pursuant to Section 269 (2) of Act no....Clinical Trial Agreement • February 14th, 2024
VZHĽADOM K TOMU, ŽE Pfizer Inc. je zadávateľom klinického skúšania („Zadávateľ alebo „Pfizer“) so skúšaným liekom ARV-471 (PF-07850327) (ďalej len "Skúšaný liek") s názvom " A PHASE 3, RANDOMIZED,OPEN-LABEL , MULTICENTER STUDY OF ARV-471 (PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2-NEGAT1VE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3) ” (ďalej len"Klinické skúšanie"), ktoré je bližšie popísané vprotokole č. C4891002, ktorý bude Zmluvným partnerom odovzdaný Zadávateľom a ktorý môže byť Zadávateľom jednostranne doplňovaný (ďalej len"Protokol"). WHEREAS, Pfizer Inc. is the Sponsor of the clinical trial (“Sponsor” or “Pfizer") involving the study drug ARV-471 (PF-07850327) (hereinafter called the “Investigational medicinal product”) named “A PHASE 3, RANDOMIZED,OPEN-LABEL MULTICENTER STUDY OF ARV-471 (PF-07850327) PLUS PALBOCICLIB VER
ContractClinical Trial Agreement • August 11th, 2017
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-419-3896 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-419-3896 This Clinical Trial Agreement (“Agreement”) is entered into as of 26/06/2017 (the “Effective Date”) by and among Thomayerova Nemocnice, a hospital with an address at Vídeňská 800, 140 59 Praha 4, Czech Republic, ID: 00064190, TIN: CZ 00064190, statecontributory organization established by the Ministry of Health of the Czech Republic, full text of foundation deed No. MZDR 17268-IV/2012 represented by doc. MUDr. Zdeněk Beneš, director (the “Institution”), doc. MUDr. Pavel Kohout, PhD., with work address at Thomayerova Nemocnice, Internal Department, pavilon B3, Vídeňská 800, 140 59 Praha 4, Czech Republic the investigator for the Trial (the “Investigator”) and Gilead Sciences, Inc., a Delaware corporation with headquarters located at 333 Lakeside Drive, Foster City, California, 94404, U.S.A. (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical
ContractClinical Trial Agreement • July 30th, 2024
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ This Clinical Trial Agreement (“Agreement”), which shall become effective as of its publication in the Register of Contracts (“Effective Date”), is by and between: Tato smlouva o klinickém hodnocení (dále jen„Smlouva“), jež nabývá účinnosti k datu zveřejnění v Registru smluv (dále jen „Datum účinnosti“), mezi: The Brigham and Women’s Hospital, Inc., a Massachusetts not-for-profit corporation with its principal place of business at 75 Francis Street, Boston, MA 02115, USA(“Sponsor”), Brigham and Women’s Hospital, Inc., nezisková organizace státu Massachusetts s hlavním sídlem na adrese 75 Francis Street, Boston, MA 02115, U.S.A.(dále jen „Zadavatel“), and a Worldwide Clinical Trials, d.o.o., having its registered office at Ulica Grada Vukovara 284, 10000 Zagreb, Croatia, ID No: 50856965346(“Worldwide“), Worldwide Clinical Trials, d.o.o., s hlavním sídlem na adrese Ulica Grada Vukovara 284, 10 000 Záhřeb,IČO společnosti: 50856965346
AGREEMENT BETWEEN THE LA PAZ UNIVERSITY HOSPITAL FOUNDATION FOR BIOMEDICAL RESEARCH, …………..………….. (INVESTIGATOR) AND ………………………… (SPONSOR) FOR THE CONDUCT OF THE CLINICAL TRIAL "………………………………………………………………..…………………………..……...."Clinical Trial Agreement • October 7th, 2017
On the one party, Mr./Mrs........................................., with Tax Identity Number .................. on behalf and in representation of .............................with registered address in ………………………………………….. and with CIF/VAT NUMBER/ID .................. (hereinafter the SPONSOR),
Republic of Ireland Model Clinical Trial Agreement between Clinical Organisations and SponsorsClinical Trial Agreement • September 18th, 2024
Add, remove and/or update recitals as applicable to the Clinical Trial (as a preamble to the Agreement, such changes do not constitute modification to the template Agreement). Appendix 6 should be completed where a corporate Affiliate of the Sponsor is formally empowered by the Sponsor to sign the Agreement on behalf of the Sponsor thereby binding the Sponsor as Party to the Agreement (and should be removed where this is not the case).
Clinical Trial AgreementClinical Trial Agreement • February 13th, 2019
This Clinical Trial Agreement (hereinafter the “Agreement”) is entered into as of the last date of execution on the signature page, between the undersigned parties (the “Validity Date”) and shall be effective on the day of its publication in the Register of Contracts in accordance with Act No. 340/2015 Coll. on the Register of Contracts, as amended (the “Effective Date”):
Clinical Trial Agreement smlouva o klinickém hodnoceníClinical Trial Agreement • September 7th, 2021
This Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení („Smlouva“) je uzavírána mezi následujícími stranami:
Clinical Trial Agreement Smlouva o klinickém hodnoceníClinical Trial Agreement • February 5th, 2020
• IQVIA RDS Czech Republic s.r.o., having a place of business at Pernerova 691/42, 186 00 Praha 8 - Karlín, Czech Republic, Identification number: 24768651, Tax identification number: CZ24768651, (“IQVIA”); and
SMLOUVAClinical Trial Agreement • July 23rd, 2018
with its registered seat at: Siemensova 2717/4, Stodůlky, 155 00 Praha 5, Czech Republic registered at the Municipal Court in Prague, Section C, Insert 391
SMLOUVAClinical Trial Agreement • May 9th, 2018
with its registered seat at: Prague 5, Stodůlky, Siemensova 2717/4, 155 00, Czech Republic registered at the Municipal Court in Prague, Section C, Insert 391
ContractClinical Trial Agreement • July 24th, 2023
Clinical Trial Agreement SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána mezi následujícími stranami: • Fakultní nemocnice Královské Vinohrady, having a place of business at Šrobárova 1150/50, 100 34 Praha 10 Identification number: 00064173, Tax identification number: CZ00064173, founded by decision of the Ministry of Health issued on 29th May 2012 No. MZDR 17266-III/2012 which modifies the decision of Minister of Health issued on 25th November 1990 No. OP-054-25.11.90 amended by modification provided in Measure of Ministry of Health issued on 31th May 2016 No. MZDR 33222/2016–2/ OPŘ, represented by MUDr. Jan Votava, MBA, Director, Reference symbol: KH 73/2022, Internal cost center No.: 34018 (the “Institution”), and • Fakultní nemocnice Královské Vinohrady, se sídlem Šrobárova 1150/50, 100 34 Praha 10, Identifikační číslo: 00064173, Daňové identifikační číslo: CZ00064173, zříze
